ESR1基因变异与次大陆基因组祖源:来自1000基因组计划与秘鲁原住民的见解
本研究基于1000基因组计划26个群体2427人及秘鲁125名原住民,推断ESR1基因变异的次大陆祖源与等位基因频率。线性回归Bonferroni校正分析显示,非洲、亚洲、欧洲和原住民群体存在次大陆分化,68个临床相关变异共发现102个关联(P<0.01),其中rs9349799与南亚成分正相关,rs2234693与海岸/亚马逊原住民负相关、与东非成分正相关。近半变异位于内含子区,强调全基因组测序对药物遗传学面板设计的重要性。
要点
- ESR1变异频率在非洲、亚洲、欧洲和原住民群体间存在次大陆差异。
- rs9349799与南亚祖源正相关,rs2234693与原住民和东非祖源相关。
- 近半ESR1临床相关变异位于内含子,支持全基因组而非仅外显子研究。
核心结论
- ESR1基因变异频率呈现次大陆祖源分化,可能影响乳腺癌治疗相关药物遗传学面板设计。
- 将原住民等代表性不足群体纳入基因组研究对实现公平有效的药物遗传学实施至关重要。
研究设计与样本
- 研究纳入1000基因组计划26个群体共2427人及秘鲁125名原住民,推断ESR1变异次大陆祖源与等位基因频率。
- 采用线性回归结合Bonferroni校正分析祖源推断与频率的关联。
主要发现
- 非洲、亚洲、欧洲和原住民群体间ESR1变异存在次大陆分化。
- 68个临床相关变异共发现102个关联(P<0.01),包括与南亚、东亚、欧洲和非洲成分的次大陆关联。
- rs9349799与南亚成分正相关,rs2234693与海岸/亚马逊原住民成分负相关、与东非成分正相关。
- 近半数变异位于内含子区。
关键数值与推荐
- 68个临床相关变异中,102个关联达到P<0.01(Bonferroni校正)。
- rs9349799与南亚祖源成分正相关;rs2234693与海岸/亚马逊原住民成分负相关、与东非成分正相关。
临床怎么用
- 设计乳腺癌药物遗传学面板时应考虑次大陆祖源差异,纳入内含子区域变异。
- 在临床药物遗传学实施中关注代表性不足人群的ESR1变异频率特征。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ESR1 gene is relevant in breast cancer treatments in the pharmacogenetics context. However, Native, African, and mixed populations are known to be underrepresented in genomic studies. This is particularly important given that the difference in variants' frequencies among different populations can lead to population-specific clinical implications. Therefore, this study aims to infer the genomic subcontinental ancestry and allele frequencies of the ESR1 gene variants in 2,427 individuals from 26 populations worldwide from the 1000 Genomes Project and 125 Natives from Peru, whose genomes have not yet been analyzed in the literature regarding this gene. Linear regression with Bonferroni correction analyses was conducted based on ancestry inference and frequencies. Our findings demonstrate subcontinental differentiation of African, Asian, European, and Native populations. Overall, 102 associations (P < 0.01) were found for 68 clinically relevant variants. Particularly, subcontinental associations were observed for variants associated with the Native, Asian, European, and African components. We highlight the findings for the rs9349799 and rs2234693 variants, previously associated with altered responses to breast cancer treatments. rs9349799 was positively associated with the South-Asian component, while rs2234693 was negatively associated with the Coast/Amazonian Native and positively associated with the East-African component. Nearly half of the variants are intronic, highlighting the importance of studying whole genomes rather than just exomes. These results emphasize subcontinental differences' relevance for designing pharmacogenetic panels. Including neglected populations in genomic and pharmacogenomic studies is essential for democratic access to scientific advances and for more egalitarian and effective pharmacogenetic implementation, tailored to each population's specificities.
引用
- Scudeler MM, Manóchio C, Miwa B, et al. ESR1 Variants and Subcontinental Genomic Ancestry: Insights from the 1000 Genomes Project and Native American Populations. Clin Pharmacol Ther. 2025. PMID: 40247433. doi:10.1002/cpt.3681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。